Puma Biotechnology (NASDAQ:PBYI) was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Monday, MarketBeat Ratings reports. The firm presently has a $93.58 price objective on the biopharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 21.69% from the stock’s current price. In […]
